Synthesis and Biological Evaluation of Folate Receptor-Targeted Boronated PAMAM Dendrimers as Potential Agents for Neutron Capture Therapy
- 15 November 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 14 (1) , 158-167
- https://doi.org/10.1021/bc025586o
Abstract
Successful treatment of cancer by boron neutron capture therapy (BNCT) requires the selective delivery of 10B to constituent cells within a tumor. The expression of the folate receptor is amplified in a variety of human tumors and potentially might serve as a molecular target for BNCT. In the present study we have investigated the possibility of targeting the folate receptor on cancer cells using folic acid conjugates of boronated poly(ethylene glycol) (PEG) containing 3rd generation polyamidoamine dendrimers to obtain 10B concentrations necessary for BNCT by reducing the uptake of these conjugates by the reticuloendothelial system. First we covalently attached 12−15 decaborate clusters to 3rd generation polyamidoamine dendrimers. Varying quantities of PEG units with varying chain lengths were then linked to these boronated dendrimers to reduce hepatic uptake. Among all prepared combinations, boronated dendrimers with 1−1.5 PEG2000 units exhibited the lowest hepatic uptake in C57BL/6 mice (7.2−7.7% injected dose (ID)/g liver). Thus, two folate receptor-targeted boronated 3rd generation polyamidoamine dendrimers were prepared, one containing ∼15 decaborate clusters and ∼1 PEG2000 unit with folic acid attached to the distal end, the other containing ∼13 decaborate clusters, ∼1 PEG2000 unit, and ∼1 PEG800 unit with folic acid attached to the distal end. In vitro studies using folate receptor (+) KB cells demonstrated receptor-dependent uptake of the latter conjugate. Biodistribution studies with this conjugate in C57BL/6 mice bearing folate receptor (+) murine 24JK-FBP sarcomas resulted in selective tumor uptake (6.0% ID/g tumor), but also high hepatic (38.8% ID/g) and renal (62.8% ID/g) uptake, indicating that attachment of a second PEG unit and/or folic acid may adversely affect the pharmacodynamics of this conjugate.Keywords
This publication has 19 references indexed in Scilit:
- PEG drugs: an overviewJournal of Controlled Release, 2001
- Immunoliposomes for the targeted delivery of antitumor drugsAdvanced Drug Delivery Reviews, 1999
- Targeting Folate Receptor with Folate Linked to Extremities of Poly(ethylene glycol)-Grafted Liposomes: In Vitro StudiesBioconjugate Chemistry, 1999
- Gadolinium(III) DO3A macrocycles and polyethylene glycol coupled to dendrimers Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agentsJournal of Alloys and Compounds, 1997
- Boronated Epidermal Growth Factor as a Potential Targeting Agent for Boron Neutron Capture Therapy of Brain TumorsBioconjugate Chemistry, 1996
- Characterization of polymers by matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry: Molecular weight estimates in samples of varying polydispersityRapid Communications in Mass Spectrometry, 1995
- Tissue distribution of 131I-labelled epidermal growth factor in the pig visualized by dynamic scintigraphyJournal of Endocrinology, 1995
- Boronated starburst dendrimer-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapyBioconjugate Chemistry, 1994
- Boron neutron capture therapy: linkage of a boronated macromolecule to monoclonal antibodies directed against tumor-associated antigensJournal of Medicinal Chemistry, 1989
- Current status of 10B-neutron capture therapy: Enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluationInternational Journal of Radiation Oncology*Biology*Physics, 1985